Sarah Bos

55 Anticoagulant activity of edoxaban in patients with cirrhosis 4 Table 1. Baseline characteristics Patients (n=16) Controls (n=16) Age 60 [48-65] 49 [42-58]* Female 6 (38) 7 (44) BMI (kg/m2) 28.7 [5] 26.4 [4.4] Diabetes 4 (25) 1 (6) CVD 5 (31) 2 (13) CTP A 15 (94) - B 1 (6) - Ascites 2 (13) - Encephalopathy 0 - BMI, body mass index, CVD, cardiovascular disease, CTP, Child Turcotte Pugh. Data are expressed as number (%), mean [SD], or median [IQR]. *p < 0.05 Baseline conventional coagulation assays At baseline, patients and healthy controls had similar fibrinogen plasma levels, 2.8 [0.9] g/l and 3.1 [0.7] g/L respectively and a comparable APTT, 34.4 [4.2] sec and 32.2 [2.7] sec. The PT, INR, prothrombin levels and d-dimer level were all significantly lower in the healthy controls compared to the patients, table 2. Table 2. Baseline coagulation parameters Patients n =16 Controls n=16 APTT, sec 34.4 [4.2] 32.2 [2.7] PT, sec 12.3 [2.4] 11.0 [0.7]* INR 1.1 [0.2] 1.0 [0.1]* Fibrinogen, g/L 2.8 [0.9] 3.1 [0.7] Prothrombin, % 65 [15] 102 [11]* D-dimer, ng/ml 517 [308-1049] 185 [124-276]* APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio. Data are expressed as mean [SD], or median [IQR]. * = p < 0.05 Hemostatic activity The ETP of patients was substantially higher at baseline, 707 [482-789] nM IIa*min, compared to controls, 403 [304-506] nM IIa*min (p < 0.05). On day 1, 3, and 7, ETP decreased in both patients and controls, but remained significantly and substantially higher in patients compared to the healthy subjects (P < 0.05). The percentual decrease of the ETP after edoxaban was significantly less in patients compared to controls at all time points (P < 0.05) (figure 1).